natgillin/translations-raw huggingface dataset:
Lamivudine Teva Pharma B.V. 300 mg film-coated tablets
Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete
Lamivudine Teva Pharma B.V. 300 mg film-coated tablets EU/1/09/596/008 20 tablets (blister)
Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete EU/1/09/596/008 20 tableta (blister)
Lamivudine Teva Pharma B.V. 300 mg film-coated tablets Lamivudine
Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete lamivudin
Lamivudine Teva Pharma B.V. and similar medicines may cause side effects in unborn babies.
Lamivudin Teva Pharma B.V. i slični lijekovi mogu uzrokovati nuspojave u nerođene djece.
Lamivudine Teva Pharma B.V. is a ‘generic medicine’.
Lamivudine Teva Pharma B.V. je „generički lijek”.
Lamivudine Teva Pharma B.V. is available in aluminium blisters containing 20, 30, 60, 80, 90, 100 and 500 tablets or HDPE containers containing 30 tablets.
Lamivudin Teva Pharma B.V. dostupan je u aluminijskim blisterima s 20, 30, 60, 80, 90, 100 i 500 tableta ili spremnicima od polietilena visoke gustoće s 30 tableta.
Lamivudine Teva Pharma B.V. is available in aluminium blisters containing 20, 30, 60, 80, 90, 100 and 500 tablets or HDPE containers containing 60 tablets.
Lamivudin Teva Pharma B.V. dostupan je u aluminijskim blisterima s 20, 30, 60, 80, 90, 100 i 500 tableta ili spremnicima od polietilena visoke gustoće sa 60 tableta.
Lamivudine Teva Pharma B.V. is used to treat HIV (human immunodeficiency virus) infection in adults and children.
Lamivudin Teva Pharma B.V. primjenjuje se za liječenje infekcija HIV-om (virusom humane imunodeficijencije) u odraslih bolesnika i djece.
Lamivudine Teva Pharma B.V. is used to treat HIV (human immunodeficiency virus) infection in adults and children.
Lamivudin Teva Pharma B.V. primjenjuje se za liječenje infekcije HIV-om (virusom humane imunodeficijencije) u odraslih bolesnika i djece.
Lamivudine Teva Pharma B.V. may be administered with or without food.
Lamivudin Teva Pharma B.V. može se uzimati s hranom ili bez hrane.
Lamivudine Teva Pharma B.V. should not be taken with any other medicinal products containing lamivudine or medicinal products containing emtricitabine (see section 4.5).
Lamivudin Teva Pharma B.V. ne smije se primjenjivati s drugim lijekovima koji sadrže lamivudin ili emtricitabin (vidjeti dio 4.5).
Lamivudine Teva will not stop you passing hepatitis B infection on to other people.
Lamivudin Teva neće spriječiti da infekciju hepatitisa B prenesete na druge ljude.
lamivudine when co-
abakavira ili lamivudina
Lamivudine+ zidovudine+efavirenz
Lamivudin+ zidovudin+efavirenz
lamivudine-resistant HBV with either compensated or decompensated liver disease, including patients pre- and post-liver transplantation or co-infected with HIV.
HBV-om rezistentnim na lamivudin i kompenziranom ili dekompenziranom bolešću jetre uključujući pacijente prije i nakon transplantacije jetre ili one istovremeno zaražene HIV-om.
Lamivudine-TP acts as a substrate for the HBV viral polymerase.
Lamivudin-trifosfat djeluje kao supstrat virusne polimeraze HBV.
Lamivudine-TP and zidovudine-TP have selective inhibitory activity against HIV-1 and HIV-2 replication in vitro; lamivudine is also active against zidovudine-resistant clinical isolates of HIV.
Lamivudin-TP i zidovudin- TP pokazuju selektivnu inhibicijsku aktivnost prema HIV-1 i HIV-2 replikaciji in vitro, a lamivudin djeluje i protiv kliničkih izolata HIV-a rezistentnih na zidovudin.
Lamivudine-TP and zidovudine-TP have selective inhibitory activity against HIV-1 and HIV-2 replication in vitro; lamivudine is also active against zidovudine-resistant clinical isolates of HIV.
Lamivudin-TP i zidovudin- TP pokazuju selektivnu inhibicijsku aktivnost prema HIV-1 i HIV-2 replikaciji in vitro, a lamivudin djeluje i protiv kliničkog izolata HIV-a rezistentnog na zidovudin.
lamivudine/300 mg raltegravir)
lamivudin/300 mg raltegravir)
Lamivudine/Tenofovir disoproxil fumarate
Lamivudin/Tenofovirdizoproksilfumar at
Lamivudine/Zidovudine Teva
Lamivudin/Zidovudin Teva
Lamivudine/Zidovudine Teva 150 mg/300 mg film-coated tablets
Lamivudin/Zidovudin Teva 150 mg/300 mg filmom obložene tablete
Lamivudine/Zidovudine Teva helps to control your condition.
Lamivudin/Zidovudin Teva Vam pomaže da kontrolirate stanje bolesti.
Lamivudine/Zidovudine Teva is a ‘generic medicine’.
Lamivudin/Zidovudin Teva je „generički lijek”.
Lamivudine/Zidovudine Teva is used to treat HIV (human immunodeficiency virus) infection in adults and children.
Lamivudin/Zidovudin Teva je namijenjen liječenju infekcija HIV-om (virusom humane imunodeficijencije) u odraslih bolesnika i djece.
Lamivudine/Zidovudine Teva should not be taken with any other medicinal products containing lamivudine or medicinal products containing emtricitabine.
Lamivudin/Zidovudin Teva se ne bi smio uzimati sa drugim lijekovima koji sadrže lamivudin ili emtricitabin.
Lamivudine/zidovudine was shown to be bioequivalent to lamivudine 150 mg and zidovudine 300 mg given as separate tablets, when administered to fasting subjects.
Pokazano je da je lamivudin/zidovudin bioekvivalentan lamivudinu od 150 mg i zidovudinu od 300 mg ako se daju bolesnicima natašte kao odvojene tablete.
Lamivudine: AUC 40%
lamivudin: AUC 40
Lamivudine: AUC 43%
lamivudin: AUC 43
Lamotrigine and
Antidepresivi i anksiolitici
lamotrigine dose adjustment is
Kolhicin u jednokratnoj
lamotrigine dose adjustment is
primjena manje doze trazodona.
lamotrigine dose may need to be
Ta kombinacija se mora
lamotrigine monitoring should be
primjenjivati s oprezom i razmotriti
Lamotrigine:
Trazodon u jednokratnoj
Lancashire BB10 2HW UK
Lancashire BB10 2HW Velika Britanija
Lancashire BL5 3XX United Kingdom
Lancashire BL5 3XX Velika Britanija
Lancashire BL5 3XX United Kingdom
Westhoughton, Bolton, Lancashire BL5 3XX Velika Britanija
Lancashire, BL5 3XX, United Kingdom
Lancashire, BL5 3XX, Ujedinjeno Kraljevstvo
Lancaster Way, Wingates Industrial Estate Westhoughton, Bolton,
Lancaster Way, Wingates Industrial Estate
Langstone Road, Havant, Hampshire PO9 1SA United Kingdom e-mail: GRA.Imaging@piramal.com
Langstone Road, Havant, Hampshire PO9 1SA Ujedinjeno Kraljevstvo e-mail: GRA.Imaging@piramal.com
Lanreotide
Lanreotid
Lansoprazol and ciclosporin may potentially inhibit CYP3A4-mediated metabolism of tacrolimus and, thereby, increase tacrolimus whole blood concentrations.
Lanzoprazol i ciklosporin mogu potencijalno inhibirati metabolizam takrolimusa posredovan CYP3A4 i time povećati koncentraciju takrolimusa u punoj krvi.
Lansoprazole
hidrokodon
Lansoprazole
lanzoprazol
Lansoprazole and ciclosporin may potentially inhibit CYP3A4-mediated metabolism of tacrolimus and thereby increase tacrolimus whole blood concentrations.
Lansoprazol i ciklosporin mogu potencijalno inhibirati metabolizam takrolimusa posredovan CYP3A4 i tako povećati koncentracije takrolimusa u punoj krvi.
Lansoprazole Rabeprazole Pantoprazole Esomeprazole Dexlansoprazole
Lanzoprazol Rabeprazol Pantoprazol Esomeprazol Dekslanzoprazol
lansoprazole,
lansoprazol, omeprazol
Lansoprazole2 Rabeprazole2 Pantoprazole2 Esomeprazole2
Lansoprazol2 Rabeprazol2 Pantoprazol2 Esomeprazol2
Lantus 100 units/ml solution for injection in a cartridge
Lantus 100 jedinica/ml otopina za injekciju u ulošku
Lantus 100 units/ml solution for injection in a cartridge for OptiClik
Lantus 100 jedinica/ml otopina za injekciju u ulošku za OptiClik
Lantus 100 units/ml solution for injection in a cartridge for OptiClik Insulin glargine
Lantus 100 jedinica/ml otopina za injekciju u ulošku za OptiClik inzulin glargin
Lantus 100 units/ml solution for injection in a cartridge for OptiClik is a clear, colourless solution.
Lantus 100 jedinica/ml otopina za injekciju u ulošku za OptiClik je bistra i bezbojna otopina.
Lantus 100 units/ml solution for injection in a cartridge insulin glargine
Lantus 100 jedinica/ml otopina za injekciju u ulošku inzulin glargin
Lantus 100 units/ml solution for injection in a vial
Lantus 100 jedinica/ml otopina za injekciju u bočici
Lantus 100 units/ml solution for injection in a vial Insulin glargine
Lantus 100 jedinica/ml otopina za injekciju u bočici inzulin glargin
Lantus 100 units/ml solution for injection Insulin glargine
Lantus 100 jedinica/ml otopina za injekciju inzulin glargin
Lantus and Toujeo (insulin glargine 300 units/ml) are not bioequivalent and are not directly interchangeable.
Lantus i Toujeo (inzulin glargin 300 jedinica/ml) nisu bioekvivalentni i nisu izravno međusobno zamjenjivi.
Lantus comes in a cartridge sealed in a plastic container, which is the disposable part of OptiClik, an Insulin Pen.
Lantus se isporučuje u ulošku ugrađenom u plastični spremnik koji je jednokratni dio inzulinske brizgalice OptiClik.
Lantus comes in a special cartridge to be used only in conjunction with the pens OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar or JuniorSTAR.
Lantus se isporučuje u posebnom ulošku koji se smije upotrebljavati samo s brizgalicama OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar ili JuniorSTAR.
Lantus comes in cartridges sealed in disposable pen injectors, OptiSet
Lantus se isporučuje u ulošcima ugrađenim u OptiSet brizgalice za jednokratnu uporabu.
Lantus in cartridge for OptiClik has been developed for use in OptiClik only.
Lantus ulošci smiju se upotrebljavati samo s brizgalicom OptiClik.
Lantus is administered subcutaneously.
Lantus se primjenjuje supkutano.
Lantus is injected under the skin.
Lantus se daje injekcijom pod kožu.
Lantus OptiSet 100 units/ml solution for injection in a pre-filled pen
Lantus Optiset 100 jedinica/ml otopina za injekciju u napunjenoj brizgalici
Lantus OptiSet 100 units/ml solution for injection in a pre-filled pen Insulin glargine
Lantus OptiSet 100 jedinica/ml otopina za injekciju u napunjenoj brizgalici inzulin glargin
Lantus OptiSet 100 units/ml solution for injection in a pre-filled pen is a clear colourless solution.
Lantus OptiSet 100 jedinica/ml otopina za injekciju u napunjenoj brizgalici je bistra i bezbojna otopina.
Lantus OptiSet 100 units/ml solution for injection Insulin glargine
Lantus OptiSet 100 jedinica/ml otopina za injekciju inzulin glargin
Lantus OPTISET solution for injection in a pre-filled pen.
Lantus OPTISET otopina za injekciju u napunjenoj brizgalici.
Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen
Lantus SoloStar 100 jedinica/ml otopina za injekciju u napunjenoj brizgalici
Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen insulin glargine
Lantus SoloStar 100 jedinica/ml otopina za injekciju u napunjenoj brizgalici inzulin glargin
Laparoscopic procedures
Laparoskopsk i postupci
Laparoscopic procedures
Laparoskopski postupci
Lapatinib + Capecitabine n = 496
Lapatinib + kapecitabin n = 496
Lapatinib alone (N = 148 )
Samo lapatinib (N = 148)
Lapatinib AUC values were approximately 3- and 4-fold higher (Cmax approximately 2.5 and 3–fold higher) when administered with a low fat (5% fat [500 calories]) or with a high fat (50% fat [1,000 calories]) meal, respectively, as compared with administration in the fasted state.
AUC vrijednosti lapatiniba bile su oko 3 do 4 puta više (Cmax oko 2,5 i 3 puta više) pri unosu s obrokom s niskim sadržajem masnoća (5% masnoća [500 kalorija]) ili obrokom s visokim sadržajem masnoća (50% masnoća [1000 kalorija], u usporedbi s primjenom u stanju gladovanja.
Lapatinib Nilotinib Erlotinib Dabrafenib Cabozantinib
Dasatinib Lapatinib Nilotinib Erlotinib Dabrafenib Kabozantinib
Lapatinib plus trastuzumab (N = 148)
Lapatinib i trastuzumab (N = 148)
Lapatinib retained significant activity against HER2- amplified breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro and was synergistic in combination with trastuzumab in these cell lines.
Lapatinib je in vitro zadržao značajnu aktivnost prema staničnim linijama raka dojke selektiranim za dugoročan rast u mediju koji sadrži trastuzumab te je u tim staničnim linijama pokazao sinergistički učinak u kombinaciji s trastuzumabom.
Lapatinib, a 4-anilinoquinazoline, is an inhibitor of the intracellular tyrosine kinase domains of both EGFR (ErbB1) and of HER2 (ErbB2) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a slow off-rate from these receptors (half-life greater than or equal to 300 minutes).
Lapatinib, 4-anilinokinazolin je inhibitor intracelularnih tirozin kinaznih domena i EFGR (ErbB1) i HER2 (ErbB2) receptora (utvrđene Kiapp vrijednosti 3nM i 13nM, po istom redoslijedu) s polaganom stopom otpuštanja s ovih receptora (poluvijek dulji ili jednak 300 minuta).
lar tachycardia,
a tahikardija,
Large cell (N = 153)
(N = 847)
Large cell (N=153)
(N=252)
Large cell (N=153)
(N=847)
Large Cell Carcinoma
Karcinom
Large decreases in lopinavir concentrations may be observed due to CYP3A induction by rifampicin.
Moguće je jako smanjenje koncentracija lopinavira zbog indukcijskog učinka rifampicina na CYP3A.
Large dog
Veliki pas
large dogs
Veliki psi
Large dogs (20 to 40 kg)
Veliki psi (20 to 40 kg)
large increase in the concentration of this
porast koncentracija ovog
large increase in the concentration of this
PREZISTE može povećati koncentracije
Large intestine perforation
perforacija debelog crijeva
large ovaries or sacs of fluids within the ovaries (ovarian cysts) of unknown origin.
povećane jajnike ili mjehuriće ispunjene tekućinom unutar jajnika (ciste jajnika) nepoznatog porijekla.
large pupils (the dark centre of the eye), problems with eyesight
proširene zjenice (tamno središte oka), poteškoće s vidom
large pupils (the dark centre of the eye), problems with eyesight
velike zjenice (tamno središte oka), poteškoće s vidom
large pupils (the dark centre of the eye), problems with eyesight, eyes feel dry
velike zjenice (tamno središte oka), poteškoće s vidom, suhe oči
large pupils (the dark centre of the eye), problems with eyesight;
proširene zjenice (tamno središte oka), poteškoće s vidom
large purple discolourations on the skin (thrombotic thrombocytopenic purpura)
velike ljubičaste mrlje na koži (trombotička trombocitopenijska purpura)
large purple discolourations on the skin (thrombotic thrombocytopenic purpura)
velike ljubičaste mrlje na koži (trombotička trombocitopenijska purpura),
Large sterile syringe to contain the final volume of reconstituted product
Velika sterilna štrcaljka koja će sadržati završni volumen otopljenog lijeka
Large sterile syringe to contain the final volume of reconstituted product
Velika sterilna štrcaljka koja će sadržati završni volumen rekonstituiranog lijeka
Larger bleeding sites used 1 to 2 grams (10-100 cm2).
Za veća mjesta krvarenja koristi se od 1 do 2 grama (10-100 cm2).
Larger increases in creatinine after dronedarone initiation have been reported in the postmarketing setting.
Znatnija povećanja vrijednosti kreatinina nakon početka liječenja dronedaronom prijavljena su nakon stavljanja lijeka u promet.
Larger volumes or quantities of liquid infant formula, beverage or food may be used for dosing.
Za doziranje se mogu primijeniti i veći volumeni ili količine tekuće dojenačke formule, pića ili hrane.
Laronidase is comprised of 628 amino acids after cleavage of the N-terminus.
Laronidaza se nakon cijepanja N-terminalnog kraja sastoji od 628 aminokiselina.
Laronidase is used as ‘enzyme replacement therapy’, which means that it replaces the enzyme that is missing in patients with MPS I. This controls the symptoms of MPS I, improving the patient’s quality of life.
Laronidaza se upotrebljava kao „enzimska nadomjesna terapija”, što znači da zamjenjuje enzim koji nedostaje u bolesnika s MPS I. Time se suzbijaju simptomi bolesti MPS I i poboljšava kvaliteta bolesnikova života.
Lars Forssells gata 23 112 75 Stockholm Sweden
Lars Forssells gata 23 112 75 Stockholm Švedska
Lartruvo 10 mg/mL concentrate for solution for infusion
Lartruvo 10 mg/ml koncentrat za otopinu za infuziju
Lartruvo 10 mg/mL sterile concentrate olaratumab
Lartruvo 10 mg/ml sterilni koncentrat olaratumab
Lartruvo and doxorubicin may decrease the number of white blood cells (including neutrophils).
Lartruvo i doksorubicin mogu smanjiti broj bijelih krvnih stanica (uključujući neutrofile).
Lartruvo concentrate for solution for infusion (sterile concentrate) is a clear to slightly opalescent and colourless to slightly yellow liquid supplied in a glass vial with a rubber stopper.
Lartruvo koncentrat za otopinu za infuziju (sterilni koncentrat) je bistra do blago opalescentna te bezbojna do bljedožuta tekućina u staklenoj bočici s gumenim čepom.
Lartruvo has been associated with infusion reactions (see section 2 “Warnings and precautions”).
Lartruvo se povezuje s reakcijama na infuziju (pogledajte odlomak 'Upozorenja i mjere opreza' u dijelu 2.).
Lartruvo has been given ‘conditional approval’.
Za lijek Lartruvo izdano je „uvjetno odobrenje”.
Lartruvo has been investigated in one main study involving 133 adults with advanced soft tissue sarcoma who couldn’t undergo surgery or radiotherapy and who had not been previously treated with anthracyclines (a group of cancer medicines that includes doxorubicin).
Lartruvo je ispitivan u jednom glavnom ispitivanju koje je uključivalo 133 odrasla bolesnika s uznapredovalim sarkomom mekog tkiva koji nisu mogli biti podvrgnuti kirurškom zahvatu ili radioterapiji i koji prije nisu bili liječeni antraciklinima (skupina lijekova protiv raka koja uključuje doksorubicin).
Lartruvo plus doxorubicin (n = 66)
Lartruvo plus doksorubicin (n = 66)
Laryngeal oedema
edem larinksa
Laryngeal oedema, hypoxia, tachypnoea
Edem larinksa, hipoksija, tahipneja
Laryngeal oedemae, dyspnoeab,c,e,
Edem larinksae, dispnejab,c,e,
Laryngitis
laringitis
Laryngitis,
laringitis,
Laryngoedema
laringealni edem
Laryngospasm (tightening of the vocal cords causing difficult and noisy breathing)
laringospazam (glasnice se stisnu i prouzroče otežano i šumno disanje)
laryngospasmb
laringospazamb,
Las Salinas 08830 Sant Boi de Llobregat Barcelona
Las Salinas, Sant Boi de Llobregat 08830 Barcelona
Last Observation Carried Forward
Zadnje zapažanje preneseno dalje
Last Observation Carried Forward
Zadnje zapažanje preneseno dalje (LOCF)
Last Observation Carried Forward imputation
Prenijeta pripisana vrijednost zadnjeg opažanja.
Late onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour).
Rijetko su zabiljeţeni neurološki poremećaji s kasnim nastupom (hipertonija, konvulzija, abnormalno ponašanje).
Late responders (N=141)
Bolesnici s kasnim odgovorom (N= 141)
Late responders (N=75)
Bolesnici s kasnim odgovorom (N= 75)
Late-onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour).
Rijetko su prijavljeni i neurološi poremećaji s odgođenim nastupom (hipertonija, konvulzije, poremećaj ponašanja).
Late-onset Pompe disease
Kasni oblik Pompeove bolesti
Late-onset Pompe disease2
Kasni oblik Pompeove bolesti2
Late-onset Pompe disease; other clinical trials and analyses
Kasni oblik Pompeove bolesti; ostala klinička ispitivanja i analize
Later, your doctor may suggest that you or your caregiver learn how to inject Abseamed under the skin (subcutaneously) yourself.
Kasnije Vaš liječnik može predložiti da Vi ili Vaš njegovatelj naučite kako sami davati Abseamed pod kožu (supkutano).
Later, your doctor may suggest that you or your caregiver learn how to inject Binocrit under the skin (subcutaneously) yourself.
Kasnije Vaš liječnik može predložiti da Vi ili Vaš njegovatelj naučite kako sami davati Binocrit pod kožu (supkutano).
Later, your doctor may suggest that you or your caregiver learn how to inject Epoetin alfa HEXAL under the skin (subcutaneously) yourself.
Kasnije Vaš liječnik može predložiti da Vi ili Vaš njegovatelj naučite kako sami davati Epoetin alfa HEXAL pod kožu (supkutano).
Later, your doctor may suggest that you or your caregiver learn how to inject it under the skin (subcutaneously) yourself.
Kasnije, Vaš liječnik Vam može predložiti da Vi ili Vaš njegovatelj naučite sami injicirati lijek pod kožu (supkutano).
Lateral temporal lobes (lt, axial review)
Lateralne temporalne režnjeve (It, aksijalni prikaz)
Latex sensitivity
Preosjetljivost na lateks
Latex-sensitive individuals
Osobe osjetljive na lateks
Latex: The needle cap of the MYCLIC pen is made from latex (dry natural rubber).
Lateks: poklopac igle napunjene brizgalice MYCLIC napravljen je od lateksa (suhe prirodne gume).
Latex: The needle cover is made from latex (dry natural rubber).
Lateks: poklopac igle napravljen je od lateksa (suhe prirodne gume).
Latin America; 11 countries
Latinska Amerika; 11 država
Latuda 18.5 mg film-coated tablets
Latuda 18,5 mg filmom obložene tablete
Latuda 18.5 mg film-coated tablets are white to off-white, film-coated round tablets debossed with “LA”
Latuda 18,5 mg filmom obložene tablete su bijele do gotovo bijele, filmom obložene okrugle tablete s utisnutim „LA“
Latuda 18.5 mg film-coated tablets Latuda 37 mg film-coated tablets Latuda 74 mg film-coated tablets lurasidone
Latuda 18,5 mg filmom obložene tablete Latuda 37 mg filmom obložene tablete Latuda 74 mg filmom obložene tablete lurasidon
Latuda 18.5 mg film-coated tablets: white to off-white, film-coated round tablets of 6 mm debossed with ‘LA’
Latuda 18,5 mg filmom obložene tablete: bijele do gotovo bijele, filmom obložene okrugle tablete promjera 6 mm s utisnutim „LA“
Latuda 37 mg film-coated tablets
Latuda 37 mg filmom obložene tablete
Latuda 37 mg film-coated tablets are white to off-white, film-coated round tablets debossed with “LB”
Latuda 37 mg filmom obložene tablete su bijele do gotovo bijele, filmom obložene okrugle tablete s utisnutim „LB“
Latuda 37 mg tablets lurasidone
Latuda 37 mg tablete lurasidon
Latuda 37 mg: film-coated tablets: white to off-white, film-coated round tablets of 8 mm debossed with ‘LB’
Latuda 37 mg filmom obložene tablete: bijele do gotovo bijele, filmom obložene okrugle tablete promjera 8 mm s utisnutim „LB“
Latuda 74 mg film-coated tablets
Latuda 74 mg filmom obložene tablete
Latuda 74 mg film-coated tablets are pale green, film-coated oval tablets debossed with “LD”.
Latuda 74 mg filmom obložene tablete su blijedo zelene, filmom obložene ovalne tablete s utisnutim „LD“.
Latuda 74 mg film-coated tablets: pale green, film-coated oval tablets of 12 mm x 7 mm debossed with ‘LD’
Latuda 74 mg filmom obložene tablete: blijedo zelene, filmom obložene ovalne tablete veličine 12 mm x 7 mm s utisnutim „LD“
Latuda 74 mg tablets lurasidone
Latuda 74 mg tablete lurasidon
Latuda should not be used in patients with ESRD unless the potential benefits outweigh the potential risks.
Latuda se ne smije koristiti u bolesnika sa završnim stadijem bubrežne bolesti, osim ako potencijana korist ne nadjačava potencijalni rizik.
Latvia/ Latvija
Latvija
LAVENTAIR 55 micrograms/22 micrograms inhalation powder, pre-dispensed
LAVENTAIR 55 mikrograma/22 mikrograma prašak inhalata, dozirani
LAVENTAIR 55 micrograms/22 micrograms inhalation powder, pre-dispensed umeclidinium/vilanterol
LAVENTAIR 55 mikrograma/22 mikrograma prašak inhalata, dozirani umeklidinij/vilanterol
LAVENTAIR 55/22 mcg inhalation powder umeclidinium/vilanterol
LAVENTAIR 55/22 µg prašak inhalata umeklidinij/vilanterol
LAVENTAIR 55/22 micrograms also showed statistically significant improvements compared with placebo in change from baseline in lung volume measures at trough and at 3 hours post dose at Week 12 in the first study (inspiratory capacity: 237 ml and 316 ml respectively, residual volume: -466 ml and -643 ml respectively and functional residual capacity: -351 ml and -522 ml respectively; all p<0.001).
U prvom je ispitivanju LAVENTAIR od 55/22 mikrograma u 12. tjednu pokazao i statistički značajna poboljšanja u usporedbi s placebom s obzirom na promjenu plućnog volumena izmjerenog na kraju intervala doziranja i 3 sata nakon primjene doze u odnosu na početnu vrijednost (udisajni kapacitet: 237 ml odnosno 316 ml, rezidualni volumen: -466 ml odnosno -643 ml i funkcionalni rezidualni kapacitet: -351 ml odnosno -522 ml; p<0,001 za sve).